Medtronic (MDT) Cash from Financing Activities (2014 - 2026)

Medtronic has disclosed Cash from Financing Activities across 13 years of filings, most recently posting -$343.0 million for Q3 2026.

• In Q3 2026, Cash from Financing Activities rose 75.16% year-over-year to -$343.0 million; the TTM figure through Jul 2026 stood at -$3.7 billion (up 25.9% YoY), while the FY2026 annual figure was -$4.8 billion, down 8.94% from the prior year.
• Cash from Financing Activities came in at -$343.0 million for Q3 2026 at Medtronic, up from -$888.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $3.0 billion in Q4 2022 to a low of -$4.9 billion in Q2 2023.
• Average Cash from Financing Activities over 5 years is -$1.2 billion, with a median of -$1.2 billion recorded in 2022.
• Year-over-year, Cash from Financing Activities surged 360.95% in 2022 and slumped 493.33% in 2024.
• Over 5 years, Cash from Financing Activities stood at $3.0 billion in 2022, then tumbled by 102.99% to -$90.0 million in 2023, then tumbled by 493.33% to -$534.0 million in 2024, then advanced by 26.03% to -$395.0 million in 2025, then advanced by 13.16% to -$343.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$343.0 million in Q3 2026, -$888.0 million in Q2 2026, and -$2.1 billion in Q1 2026.